150712-24-6 Usage
General Description
5-Benzyl-1H-pyrazol-3-amine is a chemical compound with the molecular formula C11H12N4. It is a pyrazole derivative, which is commonly used in organic synthesis and pharmaceutical research. This chemical has a benzene ring attached to the pyrazole core structure, giving it unique properties and potential biological activities. It has been studied for its potential use in the development of new antifungal, antimicrobial, and anti-inflammatory drugs. Additionally, it has been investigated for its potential as a building block in the synthesis of various heterocyclic compounds. Overall, 5-Benzyl-1H-pyrazol-3-amine is a versatile and important chemical in the field of medicinal and organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 150712-24-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,0,7,1 and 2 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 150712-24:
(8*1)+(7*5)+(6*0)+(5*7)+(4*1)+(3*2)+(2*2)+(1*4)=96
96 % 10 = 6
So 150712-24-6 is a valid CAS Registry Number.
InChI:InChI=1/C10H11N3/c11-10-7-9(12-13-10)6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H3,11,12,13)
150712-24-6Relevant articles and documents
5- OR 7-AZAINDAZOLES AS BETA-LACTAMASE INHIBITORS
-
Page/Page column 41; 43; 44, (2020/09/19)
The present invention relates to β-lactamase inhibitors having the following general formula (I): wherein R1-R4 and X1-X2 are defined in the specification, pharmaceutical composition thereof, and use thereof for the treatment of a bacterial infection, alone or in combination with β-lactam antibiotics and/or other antibiotics and/or other β-lactamase inhibitors.
HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2
-
Page/Page column 29, (2009/10/21)
The present invention relates to compounds of formula (I) wherein R1, R2, X, Y and Z are as defined in the specification.
PYRROLOTRIAZINE KINASE INHIBITORS
-
Page/Page column 15, (2008/06/13)
The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of such as TrkA, TrkB, TrkC, Jak2, Jak3 and CK2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
